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KEY POINTS 
1. FL-infiltrating stromal cells overexpress CXCL12 that triggers FL B-cell migration, 
adhesion, and activation 
2. Polarization into CXCL12hi stroma involves IL-4pos TFH, unlike TNFpos malignant B 
cells, revealing an indirect protumoral activity of FL-TFH 
 
ABSTRACT 
 
Follicular lymphoma (FL) is the most frequent indolent lymphoma and is 
characterized by the accumulation of germinal center-derived malignant B cells 
engaged in a bidirectional crosstalk with their supportive microenvironment in 
invaded lymph nodes (LN) and bone marrow (BM). T follicular helper cells (TFH) and 
infiltrating stromal cells have been shown to favor FL B-cell growth but the 
mechanisms of their protumoral effect and how LN/BM microenvironment is 
converted into a lymphoma-permissive cell niche remain poorly understood. We 
demonstrated here that FL-infiltrating LN and BM stromal cells overexpressed 
CXCL12 in situ. IL-4hi FL-TFH, unlike FL B cells themselves, triggered CXCL12 
upregulation in human stromal cell precursors. In agreement, expression of CXCL12 
was associated with IL-4 expression and signaling within the FL BM and LN niches. 
This IL-4/CXCL12 axis was amplified in activated lymphoid stromal cells as shown in 
our in vitro model of human lymphoid stroma differentiation and in an inducible 
mouse model of ectopic lymphoid organ formation. Finally, CXCL12 triggered primary 
FL B-cell activation, migration, and adhesion, a process antagonized by Btk and PI3K 
inhibitors. These data identified the IL-4/CXCL12 loop as a previously unrecognized 
pathway involved in lymphoid stroma polarization and as a potential therapeutic 
target in FL patients.  
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INTRODUCTION 
 
Tumors are now considered as a complex ecosystem in which the dynamic and 
mutualistic interactions between cancer cells and their surrounding microenvironment 
drive the coevolution of malignant cells and their supportive niche throughout the life 
history of the tumor1. Cancer-associated fibroblasts (CAFs) have been recently 
recognized as key players of cancer microenvironment with critical roles in tumor 
initiation, progression, metastatic dissemination, immune escape, and drug 
resistance. CAFs make up a highly heterogeneous population of activated 
reprogrammed myofibroblasts exhibiting specific phenotype, proliferation rate, gene 
expression profile, and epigenetic features2. They are supposedly derived from 
mesenchymal precursors, including mesenchymal stromal cells (MSCs), that could 
differentiate locally or are recruited from bone marrow (BM) or neighboring adipose 
tissue3,4. Whereas tumor cells contribute to the polarization of protumoral CAFs, 
infiltrating immune cells also shape the recruitment and activation of stromal cells 
inside tumors5. Myeloid cells were proposed as major drivers of stroma activation, 
but B and T cells could also modulate stroma functions. Such crosstalk has been well 
described in normal secondary lymphoid organs where adaptive immune cells are 
known to produce factors, in particular tumor necrosis factor alpha (TNF) and 
lymphotoxin α1β2 (LT) that cooperate to support differentiation and maintenance of 
lymphoid stromal cells, including T-cell zone fibroblastic reticular cells (FRCs) and B-
cell zone follicular dendritic cells (FDCs)6-8. Whereas CAFs could display some 
features of lymphoid stromal cells9,10, the precise relationship between CAFs and 
lymphoid stroma is not well understood. 
Follicular lymphoma (FL), the most frequent indolent lymphoma, is characterized by a 
long preclinical stage, a slow clinical course with multiple relapses, and a strong 
dependence on a specific microenvironment, including in particular CD4pos T cells 
and stromal cells11,12. FL-infiltrating T cells are enriched for activated T follicular 
helper cells (TFH) able to sustain survival of malignant B cells in vitro and 
characterized by a specific cytokine profile13,14. TFH-derived IL-4 has been shown to 
directly trigger FL B-cell activation as indicated by STAT6 phosphorylation15, 
upregulation of surface IgM16, and induction of CCL22 and CCL17 secretion17. 
Moreover, IL-4 could indirectly contribute to the polarization and organization of the 
FL protumoral cell niche. In particular, IL-4 is a well-known inducer of dendritic cell-
For personal use only.on February 17, 2017. by guest  www.bloodjournal.orgFrom 
PANDEY et al. CXCL12 regulation in lymphoma-infiltrating stroma 
 4 
specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN), a 
mannose-binding lectin recently implicated in the antigen-independent triggering of 
FL BCR by tumor-associated macrophages16. Whether IL-4 could modulate the 
properties of FL-infiltrating stromal cells has never been explored.  
As expected for a malignancy resulting from the transformation of germinal center 
(GC)-derived B cells, FL-CAFs essentially display some features of lymphoid stromal 
cells18. Accordingly, the typical BM infiltration pattern of FL is characterized by a local 
enrichment of CD4pos T cells19 and ectopic development of an heterogeneous 
population of lymphoid-like stromal cells20,21. This emphasizes the pivotal role of 
these two cell subsets in FL pathogenesis and a potential common stromal program 
in FL lymph nodes (LN) and BM. We previously demonstrated that MSCs obtained 
from FL-BM (FL-MSCs) exhibit a specific gene expression profile compared with 
MSCs from healthy donor BM (HD-MSCs) including an enrichment of a lymphoid 
stroma signature, associated with an increased capacity to sustain malignant B-cell 
growth22. In addition, FL-MSCs produce higher levels of both CCL2 and IL-8, whose 
secretion is upregulated in HD-MSCs by FL B cells22,23. These data indicate that a 
dynamic reciprocal cooperation program is activated between FL B cells and FL-
infiltrating stromal cells and results in the formation of the lymphoma-permissive 
stromal cell niche. Little is known about how lymphoma B cells get access to and are 
retained within their tumor niches inside LN and BM but both CXCR4 and CCR7 
have been involved in these processes24,25.  
Aiming at a better understanding of FL-stroma protumoral phenotype, we unraveled a 
specific upregulation of CXCL12 in both LN- and BM-infiltrating stromal cells. 
Moreover, we revealed that CXCL12 induction was not related to a crosstalk with 
TNF-producing malignant B-cells but with IL-4-producing FL-TFH. Interestingly, such 
IL-4/CXCL12 loop was also efficient in activated lymphoid-like stromal cells both in 
vitro and in vivo and should be considered as a previously unrecognized pathway 
involved in lymphoid stroma polarization. Finally, the demonstration that CXCL12 
favored malignant B-cell migration, adhesion, and activation argued for considering 
IL-4/ CXCL12 loop as a therapeutic target to disrupt FL protective cell niches. 
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PATIENTS, MATERIALS, AND METHODS 
 
Human tissue and cell samples 
Subjects were recruited under institutional review board approval following informed 
consent process according to the declaration of Helsinki and the French National 
Cancer Institute (INCa) ethic committee recommendations. Lipoaspiration was 
performed from adults undergoing abdominal dermolipectomy. Adipose-derived 
stromal cells (ADSCs) were obtained as previously described from the stromal 
vascular fraction, were maintained in αMEM medium supplemented with 10% FCS 
(HyClone), 1 ng/mL of bFGF (Cellgenix), penicillin, and streptomycin and were used 
between passages 1 and 326. BM aspirates were obtained from FL patients and age-
matched HD undergoing cardiac surgery, BM plasma was frozen, and HD- and FL-
MSCs were obtained as previously described22. Tonsils were obtained from children 
undergoing routine tonsillectomy. LN and BM biopsies were also obtained from FL 
patients. Tonsil and FL B cells were purified using the B-cell isolation kit II (Miltenyi 
Biotec). FL-TFH were sorted using a FACSAria (BD Biosciences) as described
13. 
 
Immunohistofluorescence and Immunohistochemistry 
Tonsils, FL-LN, and non-invaded/invaded FL-BM were embedded in OCT (Tissue-
Tek OCT Compound). Tonsils and FL-LN sections where analyzed for CXCL12, 
podoplanin, and CD21 long isoform (CD21L) whereas BM sections were analyzed for 
CXCL12 and CD20 expression. Immunohistochemistry for pSTAT6 and CXCL12 was 
applied to a tissue microarray of 195 formalin-fixed, paraffin-embedded tissue 
specimens from 186 patients diagnosed with FL27,28. For details, see online 
Supplemental file. 
 
Chemokine quantification  
CXCL12 was quantified on culture supernatants of ADSCs treated or not with 
TNF/LT or IL-4 and BM plasma obtained from HD and FL patients by ELISA (R&D 
system).  
 
Real time quantitative PCR  
RNA extraction from human cell suspensions and mouse tissues was done using 
RNeasy Kit (Qiagen). Human tissue sections were homogeneized using QIAzol lysis 
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reagent RNA (Qiagen) and RNA was extracted by phenol/chloroform. cDNA was 
synthesized using Superscript II reverse transcriptase, followed by RT-QPCR. Assay-
on-demand primers, probes, and TaqMan Universal Master Mix were obtained from 
Life Technologies. Gene expression was measured using StepOnePlus (Life 
Technologies) based on ΔCt calculation method. CDKN1B, EIF2B1, PUM1 were 
determined as appropriate internal controls for ADSCs and B2M, CASC3 for human 
LN and BM tissue samples, using TaqMan Endogenous Control Assays (Life 
Technologies). For mice samples, Pdgfrβ was used as an endogenous control. For 
each sample, the Ct value for the gene of interest was determined and normalized to 
its respective mean value of housekeeping genes. 
 
Stromal cell stimulation 
ADSCs were treated using TNF (20ng/mL)/LT (100ng/mL) or IL-4 (5ng/mL) (R&D 
Systems) for 3 days. When indicated, ADSCs were cultured in the presence of 
TNF/LT for 3 days and then cells were treated or not with IL-4 for 3 additional days. 
Purified FL-TFH (10
5/mL) or FL B cells (5x105 cells/mL) were cocultured with confluent 
ADSCs for 48hrs before sorting of CD45negCD105posDAPIneg viable stromal cells and 
CXCL12 quantification by RQ-PCR. 
 
Immunofluorescence 
ADSCs stimulated with TNF/LT or IL-4 for 3 days were analyzed as described 
previously29. In brief, cells were fixed in 2% PFA and stained with rat anti–podoplanin 
and mouse anti-transglutaminase (TGM2) antibodies (Abcam) followed by labeling 
with anti-rat Alexa 488 and anti-mouse Alexa 594 secondary antibodies (Jackson 
Immunoresearch). Coverslips were mounted with Mowiol including Sytox blue (Life 
Technologies) and examined using confocal microscope (SP5X, Leica Microsystem). 
Digital images were analyzed by ImageJ software.  
 
Flow cytometry  
Viable cells were analyzed after DAPIpos or TOPRO-3pos cell exclusion (Life 
Technologies) using following monoclonal antibodies (mAbs): FITC-conjugated anti-
CD19 and anti-CD20, PE-conjugated anti-CD106/VCAM-1 and anti-CD54/ICAM-1 
(Beckman Coulter), PC7-conjugated anti-CXCR4, and PC5.5-conjugated anti-
podoplanin/gp38 (eBioscience). Appropriate isotype-matched mAbs were used to 
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obtain mean fluorescence intensity (MFI) ratios and analyses were performed using 
CyAn or Gallios (Beckman Coulter) flow cytometers.  
 
Mice and salivary gland cannulation  
Balb/c, Il4-rαko and Il4ko mice were bred and maintained under specific pathogen-
free conditions in the Biomedical Service Unit at the University of Birmingham 
according to Home Office and local ethics committee regulations. The submandibular 
glands of female wild-type and knock-out mice (8-12 weeks old) were intraductally 
cannulated with 108-109 p.f.u. of luciferase-encoding replication-defective adenovirus 
(Ad5), as previously described30. Salivary glands were harvested at various time 
points post cannulation and used for evaluation of luciferase activity and 
quantification of gene expression.  
 
Cell signaling 
ADSCs were treated or not with TNF/LT for 24hrs, then starved for 2 hours in RPMI-
1%FCS before stimulation with IL-4 (5ng/mL) for 5min. FL B cells were starved for 4 
hours, treated or not for 30min by Ibrutinib (Selleckchem, 10μM), and stimulated by 
beads alone or CXCL12-Fc coated beads at 30μg/mL for 60min. Analysis of IL-4-
driven and CXCL12-driven signaling was performed as detailed in the Supplemental 
Methods.  
 
Migration and adhesion assays 
Purified FL B cells were treated or not with Idelalisib/CAL101 (5μM, Cayman 
Chemicals), Ibrutinib (10μM) or AMD3100 (1μM, Sigma) for 30min and were used for 
migration and adhesion to CXCL12 as detailed in the Supplemental Methods.  
 
Statistical analysis 
Statistical analyses were performed using Prism software version 6 (GraphPad 
Software Inc) using the non-parametric Wilcoxon test for matched pairs or the Mann-
Whitney nonparametric U test as appropriate. For association analysis between 
CXCL12 and pSTAT6 expression in human FL tissue biopsies we performed a Chi-
square test. 
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RESULTS 
 
CXCL12 is upregulated within FL stromal cell niches  
To decipher the driving signaling involved in the recruitment and homing of malignant 
FL B cells to their supportive cell niche, and given the key role of CXCL12 in normal 
GC organization, we first decided to evaluate the expression of CXCL12 by tumor-
infiltrating stromal cells. In chronically inflamed tonsils, CXCL12-expressing stromal 
cells formed a dense meshwork in perifollicular and interfollicular areas, consisting in 
podoplanin/gp38pos fibroblastic reticular cells (FRC) (Figure 1A and S2). Inside tonsil 
GC, CXCL12 staining was always scarce and strictly restricted to CD21Lneg cells, 
whereas the CD21Lpos mature follicular dendritic cell (FDC) network was CXCL12-
negative, as previously reported in mice31. Conversely, immunohistofluorescence 
analysis revealed that CXCL12 was overexpressed in stromal cells within follicles in 
8/14 FL patients and CXCL12 mRNA was significantly upregulated in FL LN 
compared to tonsil samples (Figure 1A-B and S3). Interestingly, CXCL12 
overexpression was associated with a variable loss of the CD21L FDC marker as 
revealed by RQ-PCR and immunohistofluorescence experiments (Figure S3B).  
We next decided to focus on the BM FL cell niche and performed 
immunohistofluorescence analysis on undecalcified biopsies from FL patients with 
and without BM involvement. In the absence of infiltrating malignant B cells, CXCL12 
staining revealed a diffuse and homogeneous stromal cell network (Figure S4). BM 
sections from BM-invaded patients showed aggregates of CD20pos FL B cells with 
preferential paratrabecular localization. These B-cell infiltrated areas displayed 
increased CXCL12 labeling compared to areas outside lymphoma infiltrates (Figure 
1C). In agreement, CXCL12 quantification in BM plasma showed a 4-fold increased 
CXCL12 level in FL BM (median: 4628 pg/ml, range: 726-7968 pg/ml, n=20) 
compared to age-matched HD BM (median: 1192 pg/ml, range: 56-3796 pg/ml, n=20, 
P<0.0001) (Figure 1D). Moreover, FL BM cells demonstrated a higher expression of 
CXCL12 compared to BM cells obtained from age-matched HD (Figure 1E). Finally 
we checked CXCL12 level in FL-MSCs that have been proposed as a good in vitro 
model to study lymphoma-driven alterations of stromal microenvironment22,23. 
Interestingly, we revealed that FL-MSCs exhibited a significantly higher expression of 
CXCL12 than HD-MSCs. 
For personal use only.on February 17, 2017. by guest  www.bloodjournal.orgFrom 
PANDEY et al. CXCL12 regulation in lymphoma-infiltrating stroma 
 9 
Altogether, these data argued for an upregulation of CXCL12 within FL stromal cell 
niches and raised the question of the mechanisms underlying this upregulation, 
including the factors involved and the inducer cell type.  
 
IL-4, unlike TNF/LT, upregulates CXCL12 in stromal cells  
We previously demonstrated that human BM-MSCs could acquire in vitro a lymphoid-
like stroma phenotype, associated with an upregulation of CCL19, BAFF, CCL2 and 
IL-8, in response to TNF/LT stimulation22,23,29. We thus decided to evaluate first how 
TNF/LT modulated CXCL12 production by MSCs. For that purpose we developed a 
new in vitro model of lymphoid-stroma polarization based on adipose-derived MSCs 
(ADSCs) since adipose tissue has been identified as a precursor of lymphoid stroma 
for lymph nodes and other lymphoid structures32. Interestingly, human ADSCs, like 
BM-MSCs29, were able to acquire a FRC-like phenotype upon stimulation with 
TNF/LT, including upregulation of ICAM-1/CD54, VCAM-1/CD106, gp38/podoplanin, 
BAFF, and CCL19, and construction of a dense extracellular meshwork of 
transglutaminase and podoplanin (Figure S5). In addition, ADSCs overexpressed 
CCL2 and IL8 in response to TNF/LT. In this validated model, we demonstrated a 
significant downregulation of CXCL12, at both mRNA and protein levels, in ADSCs 
stimulated by TNF/LT (Figure 2A).  
IL-4 is the most strongly deregulated cytokine in FL33 and is known to upregulate 
VCAM-1 on dermal fibroblasts34. We thus tested the impact of IL-4 stimulation on 
ADSCs. Interestingly, IL-4 strongly increased the expression of VCAM-1 but also the 
production of CXCL12 in mesenchymal precursors (Figure 2A-B). In addition, 
whereas TNF/LT decreased transglutaminase mRNA, IL-4 triggered both 
transglutaminase expression and redistribution at the surface of stromal cells (Figure 
2B-C). Finally, IL-4 reduced podoplanin expression by ADSCs. As a whole, whereas 
TNF/LT promoted ADSC in vitro differentiation into VCAM-1pospodoplaninhiCXCL12lo 
cells, IL-4 favored a VCAM-1hipodoplaninloCXCL12hi phenotype, and both TNF/LT 
and IL-4 induced the construction of an extracellular transglutaminasepos meshwork. 
FL-TFH were proposed as the major IL-4-producing cells within the FL cell niche
14 
whereas malignant B cells produce no IL-4 but variably secrete TNF, previously 
involved in the induction of both CCL2 and IL-8 production by BM-MSCs22,23. In 
agreement, co-culture of stromal cells with TNFhi malignant B cells induced a 
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decrease in CXCL12 expression. Conversely, purified CD4posCXCR5hiPD-1hi FL-TFH 
triggered an upregulation of CXCL12 in ADSCs (Figure 2D-E).  
To further increase the relevance of these in vitro observations for FL biology, we 
evaluated the expression of IL-4 in situ in FL LN and BM. IL4 mRNA was significantly 
upregulated in both FL cell niches (Figure 3A-B), unlike the IL-4-related cytokine IL13 
(Figure S6). In agreement, we revealed by Gene Set Enrichment Analysis (GSEA) 
approach, the enrichment for an IL-4 gene signature in sorted FL B cells compared to 
normal CD19posIgDnegCD38hiCD10posCXCR4neg tonsil centrocytes, thus confirming 
the activation of IL-4 signaling in FL (Figure S7). Since quantification of IL-4-
producing cells in vivo is virtually impossible apart from IL-4 reporter mice, we 
examined STAT6 phosphorylation together with CXCL12 staining across a large 
series of FL LN samples, as previously described27 (Figure 3C). We scored a sample 
as CXCL12 positive when CXCL12 expression within FL follicles was higher than in 
reactive GC used as on-slide controls. We then examined STAT6 phosphorylation in 
CXCL12 positive (n=32) versus CXCL12 negative (n=163) tumors. We observed a 
significant increase in STAT6 phosphorylation in the CXCL12 positive FL (P=0.013, 
Figure 3D). Moreover, IL4 and CXCL12 expression were positively correlated across 
20 FL BM samples (Figure 3E) thus further confirming the relationship between IL-4 
and CXCL12 within FL cell niches. Interestingly, within FL LN, transglutaminase was 
upregulated and podoplanin downregulated (Figure S6), thus mimicking the 
phenotype of IL-4-treated stromal cells. Collectively, these results suggest that an IL-
4/CXCL12 loop is activated within FL cell niches and that IL-4 contributes to the 
phenotype of FL stroma. 
 
Lymphoid stroma commitment is associated with an increased IL-4-dependent 
CXCL12 production  
Having demonstrated that IL-4 could trigger CXCL12 expression by mesenchymal 
precursors, we decided to investigate its capacity to affect the production of CXCL12 
by differentiated lymphoid stromal cells, thus mimicking the FL cell niche context. For 
that purpose, ADSCs previously committed to lymphoid stroma differentiation in vitro 
by priming with TNF/LT were treated by IL-4. As previously reported for resting 
stromal cells, FRC-like stromal cells upregulated CXCL12 in response to IL-4 at both 
mRNA and protein levels, whereas the TNF/LT combination retained its potential to 
decrease CXCL12 expression (Figure 4A). Strikingly, committed stromal cells could 
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produce significantly higher levels of CXCL12 than their resting counterpart after 
stimulation by IL-4. Of note, the same results were obtained for transglutaminase and 
VCAM-1; both induced more efficiently on lymphoid-like cells than on ADSCs by 
exogenous IL-4 (Figure 4B). We next explored the mechanism of this increased 
sensitivity of lymphoid stroma to IL-4 signaling. IL-4 induced STAT6 phosphorylation 
in resting stromal cells but TNF/LT-pretreated stromal cells exhibited a significantly 
stronger STAT6 phosphorylation in response to IL-4, as shown by both flow 
cytometry and western blot (Figure 4C).  
In order to investigate in vivo the relevance of this IL-4/CXCL12 loop in regulating 
lymphoid stroma function we took advantage of an inducible mouse model of ectopic 
lymphoid organ formation, associated with a significant increase of lymphoid 
chemokine expression, induced by cannulation of murine salivary glands with a 
replication-deficient adenovirus30. In WT mice, Il4 was strongly upregulated upon 
infection in cannulated glands with a peak at day 8 (Figure 5A). In parallel, Cxcl12 
expression was significantly increased within salivary glands (Figure 5B). 
Interestingly, moving our analysis to Il4-/- and Il4r-/- mice revealed that a blockade of 
IL-4 signaling pathway impaired CXCL12 expression from day 8 post-cannulation. 
Taken together, these findings confirm a role of IL-4 in the induction of CXCL12 in 
inflammatory non-malignant lymphoid organs, phenocopying the observation in 
human FL samples. 
 
CXCL12 mediates FL B-cell activation 
BCR activation is instrumental in the development and maintenance of most mature 
B-cell malignancies, leading to the recent development of therapeutic BCR inhibitors. 
Chemokine receptor signaling also involved various components of the BCR 
signaling pathways and both BTK and phosphoinositide 3'-kinase isoform p110δ 
(PI3Kδ) inhibitors were shown to abrogate tumor cell migration toward stromal cell-
derived CXCL12 in chronic lymphocytic leukemia (CLL)35,36. Whereas we recently 
pointed up the efficacy of the BTK inhibitor Ibrutinib to abolish the crosstalk between 
FL B cells and tumor-associated macrophages16, no study has been designed to 
decipher how Ibrutinib or the PI3Kδ inhibitor Idelalisib could affect stroma/FL B cell 
interactions. We first evaluated CXCR4 expression in FL. Interestingly, whereas 
purified FL B cells expressed significantly higher amount of CXCR4 mRNA than their 
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normal centrocyte counterpart (Figure S8A), their membrane expression of CXCR4 
was highly variable, as could be expected given the huge amount of CXCL12 within 
FL cell niche and the well-known ligand-dependent internalization of CXCR4 (data 
not shown). In agreement, as recently suggested37, CXCR4 was re-expressed after a 
4-hour in vitro culture in the absence of CXCL12, a process that did not alter FL B-
cell survival (Figure S8B). We then evaluated primary FL B-cell migration in response 
to CXCL12 after in vitro starvation and demonstrated that it was similarly reduced in 
response to the CXCR4 inhibitor AMD3100, Ibrutinib, and Idelalisib (Figure 6A). 
Interestingly, CXCL12 expression was also mandatory to trigger FL B-cell adhesion 
to stromal cells, as shown by blocking experiments based on the use of CXCL12-Fc 
chimeric molecule or AMD3100 (Figure 6B). Moreover, same results were obtained 
using CXCL12 siRNA previously validated for their capacity to inhibit CXCL12 
production by stromal cells (Figure 6B and S9). CXCL12 was described as an 
activator of SYK, another key mediator of BCR signaling, and its downstream targets, 
including ERK, in CLL B cells38. We demonstrated here that FL B cells could also 
respond to CXCR4 triggering by SYK and ERK phosphorylation (Figure 6C). 
Moreover, Ibrutinib was able to inhibit CXCL12-dependent ERK activation in primary 
FL B cells (Figure 6D). Of note, Ibrutinib decreased slightly but significantly the 
expression of CXCR4 on primary FL B cells (Figure S8C).  
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DISCUSSION 
 
FL is a paradigm of microenvironment-dependent neoplasia and infiltrating stromal 
cells have been proposed as key organizers of FL cell niches18. However, specific 
features of FL CAFs in situ are relatively unexplored. A major emerging issue is thus 
to characterize FL stroma, looking for deregulation of tumor-supporting factors, to 
highlight the cellular and molecular determinants regulating this FL-specific stroma 
phenotype, and to evaluate the potential therapeutic impact of targeting the crosstalk 
between malignant B cells and their stromal cell niche. 
Our study revealed that FL stromal cells variably but substantially upregulated 
CXCL12, the homeostatic chemokine supporting normal GC polarization into dark 
zone (DZ) and light zone (LZ)39. Of note, immunohistochemistry studies highlighted a 
lower percentage of FL samples harboring CXCL12hi follicular stromal cells than 
immunohistofluorescence, but CXCL12 mRNA was found upregulated in the majority 
of FL patients, suggesting that CXCL12 deregulation is a recurrent feature in FL. 
Given the major role of normal GC B-cell shuttling between DZ and LZ for their 
expansion, selection, and differentiation, CXCL12 is considered as a critical regulator 
of GC responses and its expression by lymphoid stromal cells is finely controlled. An 
intriguing question is thus to identify the origin of CXCL12hi stromal cells within FL LN 
follicles. We confirmed here the disappearance of mature gp38hiCD21Lpos FDCs in 
FL patients, a quite intriguing observation for a disease targeting centrocytes. Since 
FDCs are supposed to be sessile and long-lived cells, this loss of FDC markers in FL 
follicles has been initially proposed to result from local FDC dedifferentiation40. 
However, recent results revealed that the FDC network is more dynamic than 
previously anticipated with a burst of FDC differentiation from highly proliferating 
progenitors in inflammatory context 41. These data suggest that LZ FDCs could be 
replaced in FL patients by new stromal cells. A first hypothesis is that CXCL12hi FL 
stromal cells arise from the so-called CXCL12-expressing reticular cells (CRCs) 
recently identified among gp38posCD21/35neg stromal cells of the GC DZ in mice42. 
CRCs lack the main FRC and FDC markers and were thus proposed as a distinct cell 
type even if they share a lineage precursor with both FRCs and FDCs31. Apart from 
CRCs, mouse FRCs also express CXCL12 and CRC and FRC networks are tightly 
connected. Moreover, a subset of FRCs localized in follicular regions has been very 
recently shown to contribute to B-cell homeostasis through the production of BAFF43. 
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Interestingly, we pinpointed that gp38posCD21Lneg FRC network was dense and 
activated in FL patients. Whether CRCs or follicular FRCs could be considered as 
precursors of CXCL12hi FL stroma remains to be determined. Interestingly, FRC 
activation and expansion have been proposed to rely on the delivery of LTβR signals 
by incoming naïve B and T cells in response to inflammatory stimuli44 and expression 
of LT by normal GC B cells is mandatory for mature FDC differentiation45. 
Conversely, DZ CRCs do not require LT and TNF for maintenance of CXCL12 
expression and network morphology31. In agreement, purified FL B cells exhibit a 
downregulation of LTA and LTB compared to normal GC B cells (Figure S10), thus 
providing an argument in favor of a CRC-like origin for FL stromal cells. The origin of 
CXCL12hi FL stroma in invaded BM is even more puzzling. Within mouse BM, a 
subset of mesenchymal progenitors is characterized by a strong expression of 
CXCL12 and has been described in close contact with hematopoietic stem cells, B-
cell progenitors, and long-lived plasma cells46,47. We reported here for the first time 
an upregulation of CXCL12 by human stromal cells admixed with ectopic malignant 
GC B cells. Unfortunately, the lack of relevant FL mouse model precludes cell 
tracking-based identification of FL stroma precursor cells. 
Several mechanisms could cooperate in the modification of FL stromal cells and we 
previously demonstrated that malignant B cells directly trigger upregulation of stromal 
CCL2 in a TNF-dependent manner22. Interestingly, mouse B cells respond to the IL-4 
burst associated with intestinal helminth infection by an increase in their expression 
of LT, which then interacts with LTβRpos FRCs to induce their expansion and 
reorganization48. However, such process is unlikely to take place in FL, given the 
downregulation of LT on malignant B cells. In agreement, we revealed that primary 
FL B cells were not able to stimulate in vitro CXCL12 production in stromal cells, 
whereas FL-TFH were efficient CXCL12-inducers. Several T cell-derived cytokines 
could favor CXCL12 expression by lymphoid stromal cells. In particular IL-22 could 
upregulate CXCL13 and CXCL12 in tertiary lymphoid organs thus favoring B-cell 
recruitment and autoantibody production49. In addition, IL-17 drives the differentiation 
of IL17Rcpos pulmonary stromal cells from bronchus-associated lymphoid tissues into 
gp38posCD21/35negCXCL12pos follicular stromal cells allowing GC formation in the 
absence of both FDC and LTpos B cells50. Altogether these data suggest that 
infiltrating T cells producing Th17-associated cytokines could contribute to the 
polarization of cancer-infiltrating stromal cells. Within FL cell niche, malignant B cells 
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skew the Treg/Th17 balance in favor of intratumoral Treg51 and FL-TFH poorly 
express Th17-related markers, including IL-17, IL-26, and RORC13,14. IL-17 is thus 
probably not implicated in the differentiation of FL specific stroma. Conversely, given 
the association between CXCL12 expression and IL-4 expression/signaling within FL 
cell niches, it was tempting to speculate that IL-4, the main FL-TFH-derived cytokine, 
could contribute to the stimulation of CXCL12 production by stromal cells. In 
agreement, we revealed for the first time that IL-4 could directly act on human 
mesenchymal progenitors and FRC-like cells to upregulate CXCL12, in the absence 
of LT-expressing B cells. Interestingly, IL-4 also triggered in vitro transglutaminase 
upregulation and gp38/podoplanin downregulation on stromal cells, a phenotype 
close to that identified in situ within FL cell niche, and upregulated CD106, that was 
previously reported to rescue lymphoma B cells from Rituximab-induced apoptosis52. 
IL-4 exerts thus a wide effect on tumor-supportive FL stromal cells. The source of IL-
4 within FL BM remains unknown but even if their number is reduced compared to 
LN niche, PD-1pos T cells could be detected in FL BM together with an increase of the 
CD4/CD8 T cell ratio and these TFH/TFH-like cells are likely to be involved
19,53. In 
addition, IL-4 is also involved in the polarization of FL-infiltrating macrophages16. 
Altogether, these results highlight IL-4 as a key mediator and of FL pathogenesis and 
TFH-stroma crosstalk as a new B-cell extrinsic mechanism supporting FL cell growth 
(Figure S11). 
Whereas IL-4 and TNF/LT similarly induced some FRC-like features in MSCs, they 
exerted an antagonistic activity on CXCL12 and gp38/podoplanin expression, raising 
the question of the underlying signaling pathways. Interestingly, CXCL13 is also 
regulated in an opposite way by TNF and IL-4 in monocytes and macrophages even 
if, in this case, TNF acts as an inducer and IL-4 as a repressor54. In addition, TNF-
induced classical NF-κB signaling was already shown to inhibit CXCL12 expression 
in human umbilical vein endothelial cells55,56 and in a BM stromal cell line52,53. The 
demonstration that TNF/LT-primed stromal cells became more sensitive to IL-4-
dependent CXCL12 upregulation, at least in part through an increased expression of 
STAT6 signaling molecule, deserves further investigations.  
Besides their capacity to produce CXCL12, FL stromal cells have been proposed to 
contribute directly to FL B-cell growth through the expression of CD106, hedgehog 
family proteins, or BAFF, and indirectly through the recruitment of other components 
of the supportive FL cell niche, including tumor-associated macrophages and tumor-
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associated neutrophils18,22,23. In agreement, targeting the crosstalk between 
malignant B cells and stromal cells is a promising therapeutic strategy. Among the 
possible approaches, the use of the BTK inhibitor Ibrutinib or the PI3Kδ inhibitor 
Idelalisib to impair CXCR4 signaling has been recently proposed in CLL36,57 and we 
demonstrated here its relevance in FL. Other CXCR4 antagonists58 as well as SYK 
inhibitors38 are under evaluation for their capacity to counteract CXCL12 activity in B-
cell malignancies and yielded interesting in vitro results. Targeting CXCL12 
specifically produced by a subset of pancreatic cancer CAFs is sufficient to override 
tumor immunosuppression in vivo and reveals the antitumor effects of anti-PD-L1 
immunotherapy59. This finding may have important clinical relevance in FL where 
immune-checkpoint blockade emerges as a valuable therapeutic approach. Finally, 
the use of JAK3 or STAT6 inhibitors, recently tested on CLL B cells60, may override 
the effect of IL-4 on the induction of CXCL12 expression by stromal cells, but also on 
the activation of malignant B cells, in particular in combination with inhibition of BCR 
signaling pathway61, and would be thus of potential relevance in FL patients. 
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FIGURE LEGENDS 
 
Figure 1: Expression of CXCL12 within FL cell niches 
(A) Tonsil and FL LN sections were stained with mouse IgG1 anti-CXCL12 and 
mouse IgM anti-CD21L antibodies followed by appropriate secondary antibodies. 
Dotted lines indicate normal and malignant follicles. Scale bar, 100µm. (B) CXCL12 
was quantified by QPCR in frozen tonsil (n=5) and FL-LN (n=12) sections. 
***P<0.001. (C) Sections from invaded FL BM were stained with mouse IgG1 anti-
CXCL12 and rabbit anti-CD20 antibodies followed by appropriate secondary 
antibodies. Nuclei were counterstained with SytoxBlue (white). Dotted lines indicate 
the bone. Scale bar, 100µm. Boxes indicate the areas magnified in lower panels 
including intratumoral zone (left) and extratumoral zone (right panel) where scale bar 
represents 20µm. (D) CXCL12 concentration was measured by ELISA in BM plasma 
from healthy donors (HD, n=20) and FL patients (n=20). ****P<0.0001. (E) CXCL12 
was quantified by QPCR in whole BM cells (left panel) and BM-MSCs (right panel) 
obtained from HD (n=5 and n=6; respectively) and FL patients (n=20 and n=9; 
respectively). *P<0.05. 
 
Figure 2: Characterization of stromal cell primed by TNF/LT versus IL-4 
(A) CXCL12 was quantified at RNA (QPCR, left panel) and protein (ELISA, right 
panel) levels in ADSCs treated by TNF/LT or IL-4 for 3 days. In QPCR experiments, 
an arbitrary value of 1 was assigned to untreated cells (UNT). Results represent the 
mean +/- SD from 7 experiments. *P<0.05 (B) ADSCs were stimulated by TNF/LT, 
IL-4, or left untreated (UNT) for 3 days before quantification of VCAM1, TGM2, and 
PDPN expression by QPCR  (n=7). The arbitrary value of 1 was assigned to UNT 
cells. In addition, VCAM-1/CD106 expression was evaluated by flow cytometry (n=5) 
and the ratio of mean fluorescence intensity (RMFI) was determined by comparison 
with an appropriate control isotype. *P<0.05, **P<0.01. (C) ADSCs were cultured for 
3 days with TNF/LT, IL-4, or left untreated (UNT) before fixation and 
transglutaminase and podoplanin staining. Nuclei were counterstained with 
SytoxBlue (white). Scale bars, 50µm. (D) ADSCs were co-cultured for 2 days with 
purified FL B cells expressing detectable (TNFhi, n=6) or undetectable (TNFlo, n=7) 
amounts of TNF as measured by ELISA, before sorting of CD45negCD105posDAPIneg 
viable stromal cells and CXCL12 quantification by Q-PCR. The arbitrary value of 1 
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was assigned to ADSCs cultured alone (UNT). *P<0.05, **P<0.01 (E) ADSCs were 
co-cultured for 2 days with purified FL-TFH before sorting of CD45negCD105posDAPIneg 
viable stromal cells and CXCL12 quantification by Q-PCR. Results represent the 
mean +/- SD from 4 experiments. *P<0.05. 
 
Figure 3: Expression and function of IL-4 within FL cell niches 
(A) IL4 was quantified by QPCR in frozen tonsil (n=5) and FL-LN (n=12) sections. 
*P<0.05. (B) IL4 was quantified by QPCR in whole BM cells from HD (n=5) and FL 
patients (n=20). ****P<0.0001. (C) Immunohistochemical staining for CXCL12 and 
pSTAT6 on reactive tonsil (a-b), FL LN with high CXCL12/pSTAT6 expression (c-d) 
and FL LN with low CXCL12/pSTAT6 expression (e-f), Original magnification: x100 
(a-b, scale bars, 100 μm), x200 (c-f, scale bars, 50 μm). (D) Semi-quantitative 
assessment of CXCL12 and pSTAT6 on FL tissue biopsies arranged on TMA. 
CXCL12 was scored positive when the expression was higher than in reactive GC 
and pSTAT6 was scored positive considered positive when frequent nuclear positive 
cells within the malignant follicles were observed. (E) Correlation between IL4 and 
CXCL12 expression across the 20 FL BM samples. 
 
Figure 4: Impact of IL-4 on stromal cells committed to lymphoid stroma 
(A-B) ADSCs were primed or not for 3 days with TNF/LT before treatment with 
TNF/LT, IL-4, or nothing (UNT) for 3 additional days and quantification of CXCL12, 
TGM2 and VCAM1 by QPCR. The arbitrary value of 1 was assigned to ADSC 
maintained without any cytokine during all the 6-day experiment. In addition, CXCL12 
concentration was assessed by ELISA. Results represent the mean +/- SD from 6 to 
7 experiments. *P<0.05. (C) ADSCs were primed or not for 24h with TNF/LT, starved 
for 2h, and then treated with IL4 for 5 minutes. STAT6 activation was first evaluated 
by flow cytometry (left panel) and quantified as the ratio of mean fluorescence 
intensity (RMFI) of PSTAT6 staining in IL-4 treated versus IL-4 untreated cells (n=6). 
In addition, STAT6, pSTAT6 and β-actin expression was determined by western blot 
and one representative experiment out of 2 is shown.  *P<0.05, ns: not significant.  
 
Figure 5: IL-4/CXCL12 loop in a model of inducible ectopic lymphoid organ in 
mice 
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(A) Quantitative RT-PCR analysis of mRNA transcript for Il4 in WT mice on days 0, 5, 
8, 15, and 23 post cannulation (p.c.), normalized to Pdgfrβ. Relative expression was 
calibrated to 0 p.c. salivary glands. *P<0.05; **P<0.01 versus day 0. Results 
represent two experiments with four to six glands analyzed per group. (B) 
Quantitative RT-PCR analysis of mRNA transcript for Cxcl12 in WT mice, Il4-/- mice, 
and Il4r-/- mice on days 0, 5, 8, 15, and 23 post cannulation (p.c.), normalized to 
Pdgfrβ. Relative expression was calibrated to 0 p.c. salivary glands. *P<0.05; 
**P<0.01 versus day 0. Results represent two experiments with four to six glands 
analyzed per group and are represented as the mean +/- SD. Relative expression 
was calibrated to 0 p.c. salivary glands. *P<0.05; **P<0.01. 
 
Figure 6: CXCL12 signaling and functional impact on FL B cells 
(A) Primary FL B cells pretreated or not with the CXCR4 antagonist AMD3100 or the 
Btk inhibitor Ibrutinib or PI3K-δ inhibitor Idelalisib were subjected to chemotaxis 
assay in response to CXCL12. Results are presented as the mean +/- SD of the 
migration index (n=6). *P<0.05. (B) Primary FL B cells were labeled with CFSE, 
treated or not with AMD3100, and incubated for 2h on either CXCL12-Fc coated 
wells (left panel) or ADSC confluent cell monolayer (right panel). ADSCs have been 
transduced 48h before by CXCL12 targeting siRNA or control (Ctrl) siRNA. Adhesion 
percentage was calculated by comparing the residual fluorescence after adhesion 
with the fluorescence of the input. Shown is one representative experiment out of 2 
(left) or mean +/- SD from 6 experiments (right). *P<0.05. (C) Primary FL-B cells 
were starved for 4h and stimulated with uncoated (Ctrl) or CXCL12 Fc-coated beads 
for 60min. Western Blot revealed pSyk, Syk, pErk, Erk, and β-actin. Results are 
presented as the mean +/- SD from 3 experiments and one representative 
experiment is shown. (D) Primary FL B cells were starved for 4h, and pretreated or 
not by Ibrutinib before stimulation with uncoated or CXCL12 Fc-coated beads for 
60min and quantification of pErk, Erk, and β-actin by western blot. Results are 
presented as the mean +/- SD from 4 experiments and one representative 
experiment is shown. 
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